IntelGenx Technologies Corp. | |
Stock Exchange | Other OTC |
EPS |
$0.13 |
Market Cap |
$47.04 M |
Shares Outstanding |
93.45 M |
Public Float |
92.25 M |
IntelGenx Technologies Corp. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
70.03 M |
Public Float |
66.63 M |
IntelGenx Technologies Corp. | |
Stock Exchange | Toronto Ventures Stock Exchange |
EPS |
CAD0.17 |
Market Cap |
CAD62.61 M |
Shares Outstanding |
70.03 M |
Public Float |
66.63 M |
Address |
6420 Abrams Ville Saint-Laurent Québec H4S 1X9 Canada |
Employees | - |
Website | http://www.intelgenx.com |
Updated | 07/08/2019 |
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast. It also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research and development, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. |